colorectal%20cancer
COLORECTAL CANCER
Colorectal cancer is a carcinoma arising from the luminal surface of the colon.
It is the 2nd most common cancer in women and third most common cancer in male worldwide. It commonly arises from adenomatous polyps.
It is strongly linked to age with 83% occurring in people ≥60 years old.
Rectal cancer is defined as cancerous lesions located within 12 cm of the anal verge.
Drug Information

Indication: In combination w/ fluoropyrimidine-based chemotherapy for metastatic colon or rectum carcinoma. In combination...

Indication: In combination w/ 5-fluorouracil (5-FU) & folinic acid for advanced colorectal cancer in patients w/o prio...

Indication: Alone or in combination for palliative treatment of malignant tumours, particularly of breast, colon or rectum...

Indication: Advanced colorectal cancer in combination w/ 5-fluorouracil & folinic acid in patients w/o prior chemother...

Indication: Certain megaloblastic anaemia resulting from folic acid deficiency in infant, during pregnancy, in malabsorpti...

Indication: Epidermal growth factor receptor (EGFR) expressing RAS wild-type metastatic colorectal cancer, in combination ...

Indication: In combination w/ docetaxel for locally advanced or metastatic breast cancer after cytotoxic chemotherapy fail...

Indication: In combination w/ 5-fluorouracil (5-FU) & folinic acid (FA) for adjuvant treatment of stage III (Duke's C)...

Indication: Remission of subjective & objective symptoms in head & neck, gastric, colorectal, liver, gallbladder, ...

Indication: Adults w/ wild-type RAS metastatic colorectal cancer (mCRC): 1st-line in combination w/ FOLFOX; 2nd-line in co...

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 2 days ago

The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.

Pank Jit Sin, 30 Oct 2017
Barely has the dust settled on e-cigarettes before the next cigarette replacement product, based on the heat-not-burn (HNB) principle, emerges to derail tobacco control efforts. 
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

Natalia Reoutova, 18 Sep 2019

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.